parkinson's-disease
(2)
Gregory Fischer
Gregory Fischer is the co-founder and CEO of AiM Medical Robotics, a Worcester, Massachusetts company building a portable, MRI-compatible surgical robot for neurosurgery. A robotics engineer with a PhD from Johns Hopkins, Fischer spent nearly two decades as a professor at Worcester Polytechnic Institute, where he directed the Automation and Interventional Medicine (AIM) Robotics Lab and founded the PracticePoint medtech R&D center. He turned his NIH-funded research into a company aiming to bring real-time image guidance and submillimeter robotic precision into the operating room, with a first-in-human clinical study on the horizon after a $8.1 million Series A in 2025.
Bernard Ravina
Bernard Ravina is a Johns Hopkins-trained neurologist who spent two decades treating people with dystonia before deciding the field needed a drug that did not yet exist. In 2025 he founded Vima Therapeutics in Cambridge, Massachusetts, and is its CEO, advancing VIM0423, a once-daily oral therapy aimed at the dopamine-acetylcholine imbalance behind movement disorders. The company emerged from stealth with a $60 million Series A, later extended to $100 million, and dosed its first Phase 2 dystonia patient in March 2026.